References

1 Toft P, Tønnesen E. The systemic inflammatory response to anaesthesia and surgery. Curr Anaesth Crit Care. 2008;19. doi: 10.1016/j.cacc.2008.07.009

2 MacColl H, Morton S, Vasireddy A. The metabolic response to trauma. Surgery (Oxford). 2024;42:373–7. doi: 10.1016/J.MPSUR.2024.03.001

3 Desborough JP. The stress response to trauma and surgery. 2000.

4 Dobson GP. Addressing the Global Burden of Trauma in Major Surgery. Front Surg. 2015;2. doi: 10.3389/fsurg.2015.00043

5 Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: A systematic overview. Lancet. 2000;355:773–8. doi: 10.1016/S0140-6736(99)08415-9

6 stress response to trauma and surgery | BJA: British Journal of Anaesthesia | Oxford Academic. https://academic.oup.com/bja/article/85/1/109/263834 (accessed 26 June 2020)

7 Ortega VA, Mercer EM, Giesbrecht GF, et al. Evolutionary Significance of the Neuroendocrine Stress Axis on Vertebrate Immunity and the Influence of the Microbiome on Early-Life Stress Regulation and Health Outcomes. Front. Microbiol. 2021;12.

8 Soop M, Ljungqvist O. Metabolic responses to surgical stress. Clin Nutr ESPEN. 2025;67:178–83. doi: 10.1016/J.CLNESP.2025.02.021

9 Griffiths RD, Hinds CJ, Little RA. Manipulating the metabolic response to injury. Br Med Bull. 1999;55:181–95. doi: 10.1258/0007142991902204

10 Burton D. Endocrine and metabolic response to surgery. Continuing Education in Anaesthesia, Critical Care & Pain. 2004;4:144–7. doi: 10.1093/bjaceaccp/mkh040

11 Laird AM, Miller PR, Kilgo PD, et al. Relationship of early hyperglycemia to mortality in trauma patients. Journal of Trauma - Injury, Infection and Critical Care. 2004;56:1058–62. doi: 10.1097/01.TA.0000123267.39011.9F

12 Krinsley JS. Association Between Hyperglycemia and Increased Hospital Mortality in a Heterogeneous Population of Critically Ill Patients. Mayo Clin Proc. 2003;78:1471–8. doi: 10.4065/78.12.1471

13 Adie SK, Ketcham SW, Marshall VD, et al. The association of glucose control on in-hospital mortality in the cardiac intensive care unit. J Diabetes Complications. 2023;37. doi: 10.1016/j.jdiacomp.2023.108453

14 Whitcomb BW, Pradhan EK, Pittas AG, et al. Impact of admission hyperglycemia on hospital mortality in various intensive care unit populations. Crit Care Med. 2005;33:2772–7. doi: 10.1097/01.CCM.0000189741.44071.25

15 Russo MP, Grande Ratti MF, Giunta DH, et al. Hospitalized patients with stress hyperglycemia: incidence of diabetes and mortality on follow-up. Endocrinol Diabetes Nutr. 2018;65:571–6. doi: 10.1016/j.endinu.2018.07.005

16 Drayton DJ, Birch RJ, D’souza-Ferrer C, et al. Diabetes mellitus and perioperative outcomes: a scoping review of the literature. Published Online First: 2022. doi: 10.1016/j.bja.2022.02.013

17 Duggan EW, Carlson K, Umpierrez GE. Perioperative Hyperglycemia Management: An Update. Anesthesiology. 2017;126:547–60.

18 Rassias AJ, Procopio M a. Stress response and optimization of perioperative care. Disease-a-Month. 2003;49:522–54. doi: 10.1016/S0011-5029(03)00120-2

19 Bagry HS, Raghavendran S, Carli F. Metabolic syndrome and insulin resistance: Perioperative considerations. Anesthesiology. 2008;108:506–23.

20 Alvarez MA, Portilla L, Gonzalez R, et al. Insulin response to a short stress period. Psychoneuroendocrinology. 1989;14:241–4. doi: 10.1016/0306-4530(89)90022-X

21 Li L, Messina JL. Acute insulin resistance following injury. Trends in Endocrinology and Metabolism. 2009;20:429–35.

22 Ljungqvist O. Insulin resistance and outcomes in surgery. Journal of Clinical Endocrinology and Metabolism. 2010;95:4217–9.

23 Li L, Messina JL. Acute insulin resistance following injury. Trends in Endocrinology and Metabolism. 2009;20:429–35.

24 Vigas M, Nemeth S, Jurcovicova J. The mechanism of trauma induced inhibition of insulin release MECHANISM OF TRAUMA INDUCED INHIBITION OF INSULIN RELEASE. Hormone and Metabolic Research. 1973;5. doi: 10.1055/s-0028-1093935

25 Barth E, Albuszies G, Baumgart K, et al. Glucose metabolism and catecholamines. Critical Care Medicine. 2007.

26 Jones PM, Fyles JM, Persaud SJ, et al. Catecholamine inhibition of Ca2+-induced insulin secretion from electrically permeabilised islets of Langerhans. FEBS Lett. 1987;219. doi: 10.1016/0014-5793(87)81206-1

27 Southern C, Schulster D, Green IC. Inhibition of insulin secretion from rat islets of Langerhans by interleukin-6. An effect distinct from that of interleukin-1. Biochemical Journal. 1990;272. doi: 10.1042/bj2720243

28 Barton RN. NEUROENDOCRINE MOBILIZATION OF BODY FUELS AFTER INJURY. Br Med Bull. 1985;41:218–25. doi: 10.1093/OXFORDJOURNALS.BMB.A072054

29 McCowen KC, Malhotra A, Bistrian BR. Stress-Induced Hyperglycemia. Crit Care Clin. 2001;17:107–24. doi: 10.1016/S0749-0704(05)70154-8

30 Davis G, Fayfman M, Reyes-Umpierrez D, et al. Stress hyperglycemia in general surgery: Why should we care? J Diabetes Complications. 2018;32. doi: 10.1016/j.jdiacomp.2017.11.010

31 Huang YW, Yin XS, Li ZP. Association of the stress hyperglycemia ratio and clinical outcomes in patients with stroke: A systematic review and meta-analysis. Front. Neurol. 2022;13.

32 Chan MC, Tseng J Sen, Hsu KH, et al. A minimum blood glucose value less than or equal to 120 mg/dL under glycemic control is associated with increased 14-day mortality in nondiabetic intensive care unit patients with sepsis and stress hyperglycemia. J Crit Care. 2016;34:69–73. doi: 10.1016/j.jcrc.2016.04.002

33 Park SY, Gautier JF, Chon S. Assessment of Insulin Secretion and Insulin Resistance in Human. Diabetes Metab J. 2021;45:641–54. doi: 10.4093/DMJ.2021.0220

34 Hodson DJ, Martinez-Sanchez A. Pancreatic β-cell identity, glucose sensing and the control of insulin secretion. Article in Biochemical Journal. Published Online First: 2015. doi: 10.1042/BJ20141384

35 Cobelli C, Toffolo GM, Man CD, et al. Assessment of β-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am. J. Physiol. Endocrinol. Metab. 2007;293.

36 Færch K, Borch-Johnsen K, Holst JJ, et al. Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: Does it matter for prevention and treatment of type 2 diabetes? Diabetologia. 2009;52.

37 Chen YH, Lee YC, Tsao YC, et al. Association between high-fasting insulin levels and metabolic syndrome in non-diabetic middle-aged and elderly populations: A community-based study in Taiwan. BMJ Open. 2018;8. doi: 10.1136/bmjopen-2017-016554

38 Li S, Huang S, Mo Z-N, et al. Generating a reference interval for fasting serum insulin in healthy nondiabetic adult Chinese men. Singapore Med J. 2012;53:821–5.

39 Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018;20:5–21. doi: 10.1111/dom.13129

40 Campbell JE, Drucker DJ. Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action. Cell Metab. 2013;17:819–37. doi: 10.1016/J.CMET.2013.04.008

41 Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: Similarities and differences. J Diabetes Investig. 2010;1:8–23. doi: 10.1111/j.2040-1124.2010.00022.x

42 Holst JJ. The incretin system in healthy humans: The role of GIP and GLP-1. Metabolism. 2019;96:46–55. doi: 10.1016/j.metabol.2019.04.014

43 Kim M-H, Lee M-K. The Incretins and Pancreatic β-Cells: Use of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide to Cure Type 2 Diabetes Mellitus. Korean Diabetes J. 2010;34. doi: 10.4093/kdj.2010.34.1.2

44 Holst JJ, Rosenkilde MM. GIP as a Therapeutic Target in Diabetes and Obesity: Insight from Incretin Co-agonists. Journal of Clinical Endocrinology and Metabolism. 2020;105.

45 Nauck MA, Müller TD. Incretin hormones and type 2 diabetes. Diabetologia. 2023;66.

46 Sethi JK, Vidal-Puig A. Visfatin: The missing link between intra-abdominal obesity and diabetes? Trends Mol. Med. 2005;11:344–7.

47 Jacques C, Holzenberger M, Mladenovic Z, et al. Proinflammatory Actions of Visfatin/Nicotinamide Phosphoribosyltransferase (Nampt) Involve Regulation of Insulin Signaling Pathway and Nampt Enzymatic Activity *. Published Online First: 2012. doi: 10.1074/jbc.M112.350215

48 Varma V, Yao-Borengasser A, Rasouli N, et al. Human Visfatin Expression: Relationship to Insulin Sensitivity, Intramyocellular Lipids, and Inflammation. J Clin Endocrinol Metab. 2007;92:666–72. doi: 10.1210/jc.2006-1303

49 Berndt J, Klö N, Kralisch S, et al. Plasma Visfatin Concentrations and Fat Depot-Specific mRNA Expression in Humans. 2005.

50 Esteghamati A, Alamdari A, Zandieh A, et al. Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. Diabetes Res Clin Pract. 2011;91:154–8. doi: 10.1016/j.diabres.2010.11.003

51 Kabir F, Jahan FA, Khan I, et al. Increased concentration of circulating visfatin associates with post-challenged hyperglycaemia and insulin resistance in IGT subjects. J Taibah Univ Med Sci. 2015;10:481–7. doi: 10.1016/j.jtumed.2014.12.007

52 Chang Y-H, Chang D-M, Lin K-C, et al. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev. 2011;27:515–27. doi: 10.1002/dmrr.1201

53 Fukuhara A, Matsuda M, Nishizawa M, et al. Retraction. Science (1979). 2007;318:565.2-565. doi: 10.1126/science.318.5850.565b

54 Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: A protein secreted by visceral fat that Mimics the effects of insulin. Science (1979). 2005;307:426–30. doi: 10.1126/science.1097243

55 Revollo JR, Körner A, Mills KF, et al. Nampt/PBEF/Visfatin Regulates Insulin Secretion in β Cells as a Systemic NAD Biosynthetic Enzyme. Cell Metab. 2007;6:363–75. doi: 10.1016/j.cmet.2007.09.003

56 Garten A, Schuster S, Penke M, et al. Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nat. Rev. Endocrinol. 2015;11.

57 Spinnler R, Gorski T, Stolz K, et al. The Adipocytokine Nampt and Its Product NMN Have No Effect on Beta-Cell Survival but Potentiate Glucose Stimulated Insulin Secretion. PLoS One. 2013;8. doi: 10.1371/journal.pone.0054106

58 Bordone L, Motta MC, Picard F, et al. Sirt1 Regulates Insulin Secretion by Repressing UCP2 in Pancreatic β Cells. PLoS Biol. 2005;4:e31. doi: 10.1371/journal.pbio.0040031

59 Romacho T, Azcutia V, Vázquez-Bella M, et al. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia. 2009;52:2455–63. doi: 10.1007/s00125-009-1509-2

60 Moitra J, Chiang E, Brown M, et al. Extracellular PBEF Induces Endothelial Cell Proinflammatory Gene Expression Via NF-kB Activation. 2009.

61 Sommer G, Garten A, Petzold S, et al. Visfatin/PBEF/Nampt: Structure, regulation and potential function of a novel adipokine. Clin. Sci. 2008;115.

62 Moschen AR, Kaser A, Enrich B, et al. Visfatin, an Adipocytokine with Proinflammatory and Immunomodulating Properties. The Journal of Immunology. 2007;178:1748–58. doi: 10.4049/jimmunol.178.3.1748

63 Garten A, Petzold S, Körner A, et al. Nampt: linking NAD biology, metabolism and cancer. Trends in Endocrinology and Metabolism. 2009;20.

64 Imai S, Yoshino J. The importance of NAMPT/NAD/SIRT1 in the systemic regulation of metabolism and ageing. Diabetes Obes. Metab. 2013;15.

65 Al-Suhaimi EA, Shehzad A. Leptin, resistin and visfatin: The missing link between endocrine metabolic disorders and immunity. Eur. J. Med. Res. 2013;18.

66 Saddi-Rosa P, Oliveira CS, Ma Giuffrida F, et al. Visfatin, glucose metabolism and vascular disease: a review of evidence. 2010.

67 Heo YJ, Choi S-E, Jeon JY, et al. Visfatin Induces Inflammation and Insulin Resistance via the NF- κ B and STAT3 Signaling Pathways in Hepatocytes. J Diabetes Res. 2019;2019:1–11. doi: 10.1155/2019/4021623

68 Gouranton E, Romier B, Marcotorchino J, et al. Visfatin is involved in TNFα-mediated insulin resistance via an NAD + /Sirt1/PTP1B pathway in 3T3-L1 adipocytes. Adipocyte. 2014;3:180–9. doi: 10.4161/adip.28729

69 Imai S. Nicotinamide Phosphoribosyltransferase (Nampt): A Link Between NAD Biology, Metabolism, and Diseases. Curr Pharm Des. 2009;15:20–8. doi: 10.2174/138161209787185814

70 Xie N, Zhang L, Gao W, et al. NAD + metabolism: pathophysiologic mechanisms and therapeutic potential. doi: 10.1038/s41392-020-00311-7

71 Revollo JR, Körner A, Mills KF, et al. Nampt/PBEF/Visfatin Regulates Insulin Secretion in β Cells as a Systemic NAD Biosynthetic Enzyme. Cell Metab. 2007;6:363–75. doi: 10.1016/j.cmet.2007.09.003

72 Sheta YS, Elgohary E-SA, Sharaf S. VISFATIN BETWEEN FACT AND FICTION; A MARKER OF OBESITY OR A NEW PLAYER IN THE PATHOGENESIS OF TYPE 2 DIABETES MELLITUS. 2012.

73 Arner P. Editorial: Visfatin—A True Or False Trail To Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2006;91:28–30. doi: 10.1210/jc.2005-2391

74 Audrito V, Messana VG, Deaglio S. NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation. Front. Oncol. 2020;10.

75 Maratou E, Dimitriadis G, Kollias A, et al. Glucose transporter expression on the plasma membrane of resting and activated white blood cells. Eur J Clin Invest. 2007;37:282–90. doi: 10.1111/j.1365-2362.2007.01786.x

76 Cuthbertson DP. POST-SHOCK METABOLIC RESPONSE. The Lancet. 1942;239:433–7. doi: 10.1016/S0140-6736(00)79605-X

77 Kiely A, McClenaghan NH, Flatt PR, et al. Pro-inflammatory cytokines increase glucose, alanine and triacylglycerol utilization but inhibit insulin secretion in a clonal pancreatic β-cell line. Journal of Endocrinology. 2007;195. doi: 10.1677/JOE-07-0306

78 Wrublewsky S, Rother S, Pohlemann F, et al. Heparan sulfate fine-tuned interleukin-1 (IL-1) signaling inhibits insulin secretion of grafted pancreatic islets. Science Advances . 2025;11. doi: 10.1126/sciadv.ady8566

79 Moratinos J, Carpene C, de Pablos I, et al. Role of α1‐ and α2‐adrenoceptors in catecholamine‐induced hyperglycaemia, lipolysis and insulin secretion in conscious fasted rabbits. Br J Pharmacol. 1988;94. doi: 10.1111/j.1476-5381.1988.tb11531.x

80 Royo MB. Does Perioperative Hyperglycemia Increase Risk? Should We Have Aggressive Glucose Control Perioperatively? Evidence-Based Practice of Anesthesiology. 2022;254–64. doi: 10.1016/B978-0-323-77846-6.00031-8

81 Vitek V LDCRA. The unexpected increase of serum insulin levels in patients soon after trauma. Am Surg . 1979;45:228–37.

82 Shi J, Dong B, Mao Y, et al. Review: Traumatic brain injury and hyperglycemia, a potentially modifiable risk factor. Oncotarget. 2016;7:71052–61.

83 Mohammed II, Adamu II, Barka SJ. Mathematical Model for the Dynamics of Glucose, Insulin and β-Cell Mass under the Effect of Trauma, Excitement and Stress. Modeling and Numerical Simulation of Material Science. 2019;09. doi: 10.4236/mnsms.2019.94005

84 Meguid MM, Brennan MF, Aoki TT, et al. Hormone-Substrate Interrelationships Following Trauma. Archives of Surgery. 1974;109:776–83. doi: 10.1001/ARCHSURG.1974.01360060046013

85 Li S, Huang S, Mo Z-N, et al. Generating a reference interval for fasting serum insulin in healthy nondiabetic adult Chinese men. Singapore Med J. 2012;53:821–5.